Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention

References

• Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–265.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine. 2008;26:K17–K28.
   PubMed Web of Science ®Google Scholar
• Hartwig S, Syrjänen S, Dominiak-Felden G, et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer. 2012;12(1):30.
   PubMedGoogle Scholar
• Hawkins MG, Winder DM, Ball SL, et al. Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata. Virol J. 2013;10(1):137.
   PubMedGoogle Scholar
• Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope. 2001;111(1):57–69.
   PubMed Web of Science ®Google Scholar
• Human medicine European public assessment report (EPAR): gardasil. 20 September 2006.
   Google Scholar
• Human medicine European public assessment report (EPAR): cervarix. 20 September 2007.
   Google Scholar
• Human medicine European public assessment report (EPAR): Gardasil 9. 10 June 2015.
   Google Scholar
• Joura EA, Giuliano AR, Iversen O-E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723.
   PubMed Web of Science ®Google Scholar
• Skinner SR, Apter D, De Carvalho N, et al. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Rev Vaccines. 2016;15(3):367–387.
   PubMed Web of Science ®Google Scholar
• Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325–339.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757–1765.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4· 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–1255.
   PubMed Web of Science ®Google Scholar
• Woestenberg PJ, King AJ, van Benthem BH, et al. Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors. J Infect Dis. 2017;217(2):213–222.
   Web of Science ®Google Scholar
• Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009;8(12):1663–1679.
   PubMed Web of Science ®Google Scholar
• Vaccination against cervical cancer (Gezondheidsraad, Vaccinatie tegen baarmoederhalskanker); The Hague: Health Council of the Netherlands, 2008; publication no. 2008/08E. ISBN 978-90-5549-711-9. 2008.
   Google Scholar
• Donken R, Bogaards JA, van der Klis FR, et al. An exploration of individual-and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls. Hum Vaccin Immunother. 2016;12(6):1381–1393.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453–e463.
   PubMed Web of Science ®Google Scholar
• EMA. Assessment report. EMA/653012/2011 Committee for medicinal products for human use (CHMP) 2011.
   Google Scholar
• Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10(12):845–852.
   PubMed Web of Science ®Google Scholar
• Lin A, Ong KJ, Hobbelen P, et al. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clinl Infect Dis. 2016;64(5):580–588.
   Web of Science ®Google Scholar
• Canfell K. Who should be vaccinated against HPV? BMJ. 2015;350.
   PubMedGoogle Scholar
• Castellsagué X, Schneider A, Kaufmann AM, et al. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol. 2009;115(3):S15–S23.
   PubMed Web of Science ®Google Scholar
• Grant LA, Dunne EF, Chesson H, et al. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. Vaccine. 2011;29(13):2365–2370.
   PubMed Web of Science ®Google Scholar
• Canfell K, Chesson H, Kulasingam SL, et al. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30:F157–F167.
   PubMed Web of Science ®Google Scholar
• Qendri V, Bogaards JA, Berkhof J. Pricing of HPV vaccines in European tender-based settings. The European Journal of Health Economics. 2018;1–10. doi:10.1007/s10198-018-0996-9
   PubMedGoogle Scholar
• Coupé V, Berkhof J, Bulkmans N, et al. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer. 2008;98(3):646.
   PubMed Web of Science ®Google Scholar
• Lenselink CH, Melchers WJ, Quint WG, et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One. 2008;3(11):e3743.
   PubMed Web of Science ®Google Scholar
• Mollers M, Hein JB, Henrike JV, et al. Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands. Vaccine. 2013;31(2):394–401.
   PubMed Web of Science ®Google Scholar
• Mollers M, Scherpenisse M, van der Klis FR, et al. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. Cancer Epidemiol. 2012;36(6):519–524.
   PubMed Web of Science ®Google Scholar
• Schmeink C, Massuger L, Lenselink C, et al. Prospective follow‐up of 2,065 young unscreened women to study human papillomavirus incidence and clearance. Int J Cancer. 2013;133(1):172–181.
   PubMed Web of Science ®Google Scholar
• Vriend HJ, Boot HJ, van der Sande MA. Type-specific human papillomavirus infections among young heterosexual male and female STI clinic attendees. Sex Transm Dis. 2012;39(1):72–78.
   PubMed Web of Science ®Google Scholar
• Alberts C, Vos R, Borgdorff H, et al. Vaginal high-risk human papillomavirus infection in a cross-sectional study among women of six different ethnicities in Amsterdam, the Netherlands: the HELIUS study. Sex Transm Infect. 2016. sextrans-2015–052397
   PubMed Web of Science ®Google Scholar
• Vriend HJ, Bogaards JA, van der Klis FR, et al. Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PloS one. 2013;8(4):e60696.
   PubMed Web of Science ®Google Scholar
• Van Aar F, Mooij SH, Van Der Sande MA, et al. Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. Aids. 2013;27(18):2921–2931.
   PubMed Web of Science ®Google Scholar
• Van Rijn VM, Mooij SH, Mollers M, et al. Anal, penile, and oral high-risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men. PLoS One. 2014;9(3):e92208.
   PubMed Web of Science ®Google Scholar
• Mooij SH, Boot HJ, Speksnijder AG, et al. Oral human papillomavirus infection in HIV-negative and HIV-infected MSM. Aids. 2013;27(13):2117–2128.
   PubMed Web of Science ®Google Scholar
• The Netherlands cancer registry. Online database from Netherlands Comprehensive Cancer Organisation (IKNL). Available at www.cijfersoverkanker.nl. Accessed on 8 August 2018.
   Google Scholar
• Schurink-Van’t Klooster T, de Melker H. The national immunisation programme in the Netherlands: surveillance and developments in 2016–2017. RIVM (Rapport 2017-0143); 2017. Available at www.rivm.nl.
   Google Scholar
• Schurink T, de Melker H HPV vaccination: background information for the Dutch Health Council. 2017.
   Google Scholar
• Braakhuis BJ, Visser O, Leemans CR. Oral and oropharyngeal cancer in the Netherlands between 1989 and 2006: increasing incidence, but not in young adults. Oral Oncol. 2009;45(9):e85–e89.
   PubMed Web of Science ®Google Scholar
• Rietbergen MM, Leemans CR, Bloemena E, et al. Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer. 2013;132(7):1565–1571.
   PubMed Web of Science ®Google Scholar
• Henneman R, Van Monsjou HS, Verhagen CV, et al. Incidence changes of human papillomavirus in oropharyngeal squamous cell carcinoma and effects on survival in the Netherlands cancer institute, 1980–2009. Anticancer Res. 2015;35(7):4015–4022.
   PubMed Web of Science ®Google Scholar
• Van den Broek I, Van Aar F, Van Oeffelen A et al. Sexually transmitted infections in the Netherlands in 2015. RIVM (RIVM Rapport 2016-0027); 2016. Available at www.rivm.nl.
   Google Scholar
• Visser M, Van Aar F, van Oeffelen A, et al. Sexually transmitted infections including HIV, in the Netherlands in 2016. RIVM (Rapport 2017-0003); 2017. Available at www.rivm.nl.
   Google Scholar
• Visser M, van Aar F, Op de Coul E, et al. Sexually transmitted infections in the Netherlands in 2017. RIVM (RIVM Rapport 2018-0012); 2018. Available at www.rivm.nl.
   Google Scholar
• McDonald SA, Qendri V, Berkhof J, et al. Disease burden of human papillomavirus infection in the Netherlands, 1989–2014: the gap between females and males is diminishing. Cancer Causes Control. 2017;28(3):203–214.
   PubMed Web of Science ®Google Scholar
• Boot HJ, Wallenburg I, de Melker HE, et al. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in the Netherlands. Vaccine. 2007;25(33):6245–6256.
   PubMed Web of Science ®Google Scholar
• Coupe VM, van Ginkel J, de Melker HE, et al. HPV16/18 vaccination to prevent cervical cancer in the Netherlands: model-based cost-effectiveness. Int J Cancer. 2009;124(4):970–978.
   PubMed Web of Science ®Google Scholar
• Rogoza RM, Westra TA, Ferko N, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine. 2009;27(35):4776–4783.
   PubMed Web of Science ®Google Scholar
• de Kok IM, van Ballegooijen M, Habbema JD. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst. 2009;101(15):1083–1092.
   PubMedGoogle Scholar
• de Kok IM, Habbema JD, van Rosmalen J, et al. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer. 2011;47(3):428–435.
   PubMed Web of Science ®Google Scholar
• Luttjeboer J, Westra TA, Wilschut JC, et al. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account. Vaccine. 2013;31(37):3922–3927.
   PubMed Web of Science ®Google Scholar
• Van’t Klooster T, Kemmeren J, Vermeer-de Bondt P, et al. Human papillomavirus vaccination catch-up campaign in 2009 for girls born 1993 to 1996 in the Netherlands in 2009: results of the post-marketing safety suveillance. 2011. RIVM (Report 210012001). Available at www.rivm.nl.
   Google Scholar
• Van’t Klooster T, Kemmeren J, Vermeer-de Bondt P, et al. Adverse events following vaccination against human papillomavirus: results of the 2010 campaign in the Netherlands. 2011. RIVM (Report 210012002). Available at www.rivm.nl
   Google Scholar
• Van’t Klooster T, Kemmeren J, Van Der Maas N, et al. Reported adverse events in girls aged 13–16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine. 2011;29(28):4601–4607.
   PubMed Web of Science ®Google Scholar
• Schurink-Van’t Klooster T, de Ridder M, Kemmeren J, et al. Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands. Eur J Pediatr. 2015;174(5):641–649.
   PubMed Web of Science ®Google Scholar
• Schurink-Van't Klooster TM, Kemmeren JMM, Ter Wolbeek M, et al. No evidence found for an increased risk of long-term fatigue following human papillomavirus vaccination of adolescent girls. Vaccine. 2018;36(45):6796–6802.
   PubMed Web of Science ®Google Scholar
• Netherlands Pharmacovigilance Centre Lareb. Overview of reports of long - lasting fatigue following immunisation with Cervarix®. 2013.
   Google Scholar
• Netherlands Pharmacovigilance Centre Lareb. Long-lasting adverse events following immunization with Cervarix®. Update 2016. 2016.
   Google Scholar
• Van Lier E, Geraedts J, Oomen P et al. Immunisation coverage and annual report national immunisation programme in the Netherlands 2017 (Vaccinatiegraad en jaarverslag Rijksvaccinatieprogramma Nederland 2017). RIVM report 2018–0008., (2018).
   Google Scholar
• Van Lier E, Oomen P, Giesbers H, et al. Immunization coverage National immunization programme in the Netherlands. RIVM Rapport. 2012;201001001:2012.
   Google Scholar
• Rondy M, Van Lier A, Van de Kassteele J, et al. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine. 2010;28(9):2070–2075.
   PubMed Web of Science ®Google Scholar
• Gefenaite G, Smit M, Nijman HW, et al. Comparatively low attendance during human papillomavirus catch-up vaccination among teenage girls in the Netherlands: insights from a behavioral survey among parents. BMC Public Health. 2012;12(1):498.
   PubMed Web of Science ®Google Scholar
• van Keulen HM, Otten W, Ruiter RA, et al. Determinants of HPV vaccination intentions among Dutch girls and their mothers: a cross-sectional study. BMC Public Health. 2013;13(1):111.
   PubMed Web of Science ®Google Scholar
• Hofman R, van Empelen P, Richardus JH, et al. Predictors of HPV vaccination uptake: a longitudinal study among parents. Health Educ Res. 2013;29(1):83–96.
   PubMed Web of Science ®Google Scholar
• Pot M, van Keulen HM, Ruiter RA, et al. Motivational and contextual determinants of HPV-vaccination uptake: a longitudinal study among mothers of girls invited for the HPV-vaccination. Prev Med. 2017;100:41–49.
   PubMed Web of Science ®Google Scholar
• Mollers M, King AJ, Knol MJ, et al. Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: results from a longitudinal Dutch cohort study. Vaccine. 2015;33(23):2678–2683.
   PubMed Web of Science ®Google Scholar
• Donken R, King AJ, Bogaards JA, et al. High effectiveness of the bivalent human papillomavirus (HPV) vaccine against incident and persistent HPV infections up to 6 years after vaccination in young Dutch women. J Infect Dis. 2018;217(10):1579–1589.
   PubMed Web of Science ®Google Scholar
• Kavanagh K, Pollock K, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110(11):2804.
   PubMed Web of Science ®Google Scholar
• Woestenberg PJ, Bogaards JA, King AJ, et al. Assessment of herd effects among women and heterosexual men following girls-only HPV16/18 vaccination in the Netherlands: a repeated cross-sectional study. International Journal of Cancer [article in press]. doi:10.1002/ijc.31989
   Google Scholar
• Donken R, Schurink-van ‘T Klooster TM, Schepp RM, et al. Immune responses after 2 versus 3 doses of HPV vaccination up to 4½ years after vaccination: an observational study among dutch routinely vaccinated girls. J Infect Dis. 2016;215(3):359–367.
   Web of Science ®Google Scholar
• Bogaards JA, Coupe VM, Xiridou M, et al. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology. 2011;22(4):505–515.
   PubMed Web of Science ®Google Scholar
• Matthijsse SM, Hontelez JA, Naber SK, et al. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination. Vaccine. 2015;33(41):5357–5364.
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Wallinga J, Brakenhoff RH, et al. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015;350:h2016.
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Xiridou M, Coupe VM, et al. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol. 2010;171(7):817–825.
   PubMed Web of Science ®Google Scholar
• Qendri V, Bogaards JA, Berkhof J. Health and economic impact of a tender-based, sex-neutral human papillomavirus 16/18 vaccination program in the Netherlands. J Infect Dis. 2017;216(2):210–219.
   PubMed Web of Science ®Google Scholar
• Westra TA, Stirbu-Wagner I, Dorsman S, et al. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis. 2013;13:75.
   PubMed Web of Science ®Google Scholar
• Harper DM, DeMars LR. HPV vaccines–a review of the first decade. Gynecologic Oncology. 2017;146(1):196–204.
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Kretzschmar M, Xiridou M, et al. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med. 2011;8(12):e1001147.
   PubMed Web of Science ®Google Scholar
• Westra TA, Rozenbaum MH, Rogoza RM, et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis. 2011;204(3):377–384.
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Coupé VM, Meijer CJ, et al. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine. 2011;29(48):8929–8936.
   PubMed Web of Science ®Google Scholar
• Matthijsse SM, Hontelez JA, Naber SK, et al. Public health benefits of routine human papillomavirus vaccination for adults in the Netherlands: a mathematical modeling study. J Infect Dis. 2016;214(6):854–861.
   PubMed Web of Science ®Google Scholar
• Corcoran B, Clarke A, Barrett T. Rapid response to HPV vaccination crisis in Ireland. Lancet. 2018;391(10135):2103.
   PubMed Web of Science ®Google Scholar
• Gilmour S, Kanda M, Kusumi E, et al. HPV vaccination programme in Japan. Lancet. 2013;382(9894):768.
   PubMed Web of Science ®Google Scholar
• Hanley SJB, Yoshioka E, Ito Y, et al. HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571.
   PubMed Web of Science ®Google Scholar
• Donegan K, Beau-Lejdstrom R, King B, et al. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine. 2013;31(43):4961–4967.
   PubMed Web of Science ®Google Scholar
• Skufca J, Ollgren J, Artama M, et al. The association of adverse events with bivalent human papilloma virus vaccination: a nationwide register-based cohort study in Finland. Vaccine. 2018; 36(39):5926–5933.
   PubMed Web of Science ®Google Scholar
• Phillips A, Patel C, Pillsbury A, et al. Safety of human papillomavirus vaccines: an updated review. Drug Safety. 2018; 41(4):329–346.
   PubMed Web of Science ®Google Scholar
• Donken R, Tami A, Knol MJ, et al. Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study. BMC Public Health. 2018;18(1):837.
   PubMedGoogle Scholar
• Burger EA, Sy S, Nygård M, et al. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PloS one. 2014;9(3):e89974.
   PubMed Web of Science ®Google Scholar
• Wolff E, Elfström KM, Cange HH, et al. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. Vaccine. 2018;36(34):5160–5165.
   PubMed Web of Science ®Google Scholar
• Brewster D, Bhatti L. Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975–2002. Br J Cancer. 2006;95(1):87.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294.
   PubMed Web of Science ®Google Scholar
• Hocking J, Stein A, Conway E, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer. 2011;104(5):886.
   PubMed Web of Science ®Google Scholar
• Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)–associated cancers and HPV vaccination coverage levels. JNCI. 2013;105(3):175–201.
   PubMed Web of Science ®Google Scholar
• Lundberg M, Leivo I, Saarilahti K, et al. Increased incidence of oropharyngeal cancer and p16 expression. Acta Otolaryngol. 2011;131(9):1008–1011.
   PubMed Web of Science ®Google Scholar
• Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high‐grade anal intraepithelial neoplasia in Denmark, 1978–2008. Int J Cancer. 2012;130(5):1168–1173.
   PubMed Web of Science ®Google Scholar
• Ramqvist T, Dalianis T. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res. 2011;31(5):1515–1519.
   PubMed Web of Science ®Google Scholar
• van der Zee RP, Richel O, De Vries H, et al. The increasing incidence of anal cancer: can it be explained by trends in risk groups. Neth J Med. 2013;71(8):401–411.
   PubMed Web of Science ®Google Scholar
• Frisch M, Smith E, Grulich A, et al. Cancer in a population-based cohort of men and women in registered homosexual partnerships. Am J Epidemiol. 2003;157(11):966–972.
   PubMed Web of Science ®Google Scholar
• Nyitray AG, Carvalho Da Silva RJ, Baggio ML, et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis. 2011;203(1):49–57.
   PubMed Web of Science ®Google Scholar
• Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28.
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–1585.
   PubMed Web of Science ®Google Scholar
• Zou H, Tabrizi SN, Grulich AE, et al. Early acquisition of anogenital human papillomavirus among teenage men who have sex with men. J Infect Dis. 2013;209(5):642–651.
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Boily M-C, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–580.
   PubMed Web of Science ®Google Scholar
• Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school-and non-school based immunization program. Vaccine. 2014;32(3):320–326.
   PubMed Web of Science ®Google Scholar
• Rehn M, Uhnoo I, Kühlmann-Berenzon S, et al. Highest vaccine uptake after school-based delivery-a county-level evaluation of the implementation strategies for HPV catch-up vaccination in Sweden. PloS one. 2016;11(3):e0149857.
   PubMed Web of Science ®Google Scholar
• Ryser MD, McGoff K, Herzog DP, et al. Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies. Epidemics. 2015;11:32–47.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095–1101.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Sasieni P, Meijer CJ, et al. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24:S78–S89.
   Web of Science ®Google Scholar
• Garattini L, van de Vooren K, Curto A. Pricing human papillomavirus vaccines. Pharmacoeconomics. 2012;30(3):213–217.
   PubMed Web of Science ®Google Scholar